Functional analysis of MFAP5 and development of new treatment agent for keloid

• Project/Area Number: 25861693
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Plastic surgery
• Research Institution: Sapporo Medical University
• Principal Investigator: IKEDA Kanae 札幌医科大学, 医学部, 研究員 (70404746)
• Project Period (FY): 2013-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000); Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
• Keywords: ケロイド / 創傷治癒

Outline of Final Research Achievements

The study of MFAP 5 was not obtained with effective results, and it was changed to resveratrol as a therapeutic agent for keloid. Type I collagen, α-smooth muscle actin, and heat shock protein 47 expression decreased in resveratrol-treated keloid fibroblasts in a dose-dependent manner. In addition, resveratrol diminished transforming growth factor-β1 production by keloid fibroblasts. We also demonstrated that it suppressed their proliferation and induced apoptosis of the fibroblasts. Our data indicate that resveratrol may have an antifibrogenic effect on keloid fibroblasts , suggesting the potential application of resveratrol for the treatment of keloids.